Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Operations (2016 - 2025)

vTv Therapeutics' Cash from Operations history spans 12 years, with the latest figure at 9251000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 91.73% year-over-year to 9251000.0; the TTM value through Dec 2025 reached 25255000.0, changed 0.21%, while the annual FY2025 figure was 25255000.0, 0.21% changed from the prior year.
  • Cash from Operations for Q4 2025 was 9251000.0 at vTv Therapeutics, down from 5222000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 706000.0 in Q2 2022 and bottomed at 9251000.0 in Q4 2025.
  • The 5-year median for Cash from Operations is 5260500.0 (2021), against an average of 5248650.0.
  • The largest annual shift saw Cash from Operations soared 117.66% in 2022 before it tumbled 973.51% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 6417000.0 in 2021, then fell by 7.22% to 6880000.0 in 2022, then surged by 57.65% to 2914000.0 in 2023, then plummeted by 65.58% to 4825000.0 in 2024, then plummeted by 91.73% to 9251000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Cash from Operations are 9251000.0 (Q4 2025), 5222000.0 (Q3 2025), and 5095000.0 (Q2 2025).